Provided are a bispecific antibody or an antigen-binding fragment thereof, a nucleic acid encoding the same, a cell comprising the nucleic acid, a composition comprising the bispecific antibody or antigen-binding fragment thereof, the nucleic acid and/or the cell, and related applications of the bispecific antibody or antigen-binding fragment thereof in the treatment of cancer.

The present disclosure relates to methods for using various markers to predict manufacturing outcomes or clinical responses of subjects, e.g., patients, to administration of a T cell therapy. In some aspects, the T cells of the T cell therapy express recombinant receptors such as chimeric receptors, e.g., chimeric antigen receptors (CARs), or other transgenic receptors, such as T cell receptors (TCRs). Also provided herein are methods for treating subjects, for instance those predicted to exhibit a clinical response.

The present invention refers to a bispecific in tandem receptor CAR, named RfuCAR, which includes a scFv that recognizes and ligates surface molecules on tumoral cells (CD33, CD123 or another tumoral target) and the IL-1 receptor type 2 (IL-1R2). According to this, the IL1-R2 was chosen as the ideal receptor to compose the RfuCAR construction, being able to capture the IL-1 with high affinity and specificity. These proprieties indicate it as a good candidate to reduce the neurotoxicity and CRS effects of CAR-T therapies. Additionally, the present invention deals with a method for modulating the tumoral microenvironment, for example, in case of acute myeloid leukemia, or other cancer type like but not restricted to acute lymbloblastic leukemia, pancreatic, lung and ovarian cancer.

Anti-V17 antibodies or antigen binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies, and methods of using the antibodies for treating or preventing diseases.

The present invention relates generally to the use of LSD1 inhibitors in connection with use and manufacture of immune effector cells (e.g., T cells, NK cells), e.g., engineered to express a chimeric antigen receptor (CAR), to treat a subject having a disease, e.g., a disease associated with expression of a tumor antigen.

The present invention relates to a humanized anti-CD28 antibody, a multispecific antibody comprising the humanized anti-CD28 antibody, especially a bispecific antibody comprising the humanized anti-CD28 antibody and an anti-CD40 antibody, a polynucleotide encoding these antibodies, a vector comprising the polynucleotide, a host cell comprising the polynucleotide or the vector, and a pharmaceutical composition comprising same. The present invention also relates to use of the humanized anti-CD28 antibody in inducing T cell proliferation and use of the bispecific antibody in enhancing the killing effect of immune cells on a target cell.

The present invention provides a bispecific chimeric antigen receptor targeting BCMA-CD19 and an application thereof. The bispecific chimeric antigen receptor comprises an extracellular antigen recognition domain; the extracellular antigen recognition domain comprises an anti-BCMA extracellular antigen recognition domain and an anti-CD19 extracellular antigen recognition domain; the anti-BCMA extracellular antigen recognition domain comprises BCMA VH and BCMA VL, wherein amino acid sequences of BCMA VH complementarity-determining regions CDR1, CDR2 and CDR3 respectively comprise amino acid sequences as represented by SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3, and amino acid sequences of BCMA VL complementarity-determining regions CDR1, CDR2 and CDR3 comprise amino acid sequences as represented by SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6.

The present invention provides therapeutics for the treatment of Multiple myeloma. In particular, the present invention provides chimeric antigen receptor (CAR) T-cells that can target the B cell maturation antigen.

An immunoresponsive cell, such as a T-cell expressing a second generation chimeric antigen receptor comprising: (a) a signalling region; (b) a co-stimulatory signalling region; (c) a transmembrane domain; and (d) a binding element that specifically interacts with a first epitope on a target antigen; and a chimeric costimulatory receptor comprising (e) a co-stimulatory signalling region which is different to that of (b); (f) a transmembrane domain; and g) a binding element that specifically interacts with a second epitope on a target antigen. This arrangement is referred to as parallel chimeric activating receptors (pCAR). Cells of this type are useful in therapy, and kits and methods for using them as well as methods for preparing them are described and claimed.

Disclosed herein are compositions and uses thereof for detecting HIV latency reversal, isolating cells with HIV latency reversal, treating HIV infection, and/or reversing latency in HIV infected CD4+ T cells. In some aspects, disclosed herein is a composition and uses thereof for treating HIV infection, wherein the composition comprises one or more mature monocyte-derived dendritic cells (MDGs) having an HIV peptide bound to a Class I major histocompatibility complex (MHC) molecule and a herpesvirus peptide bound to one or more Class II MHC molecules.